- Home
- BFST vs CVAC Comparison
BFST vs CVAC Comparison
Compare BFST & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFST
- CVAC
- Stock Information
- Founded
- BFST 2006
- CVAC 2000
- Country
- BFST United States
- CVAC Germany
- Employees
- BFST N/A
- CVAC N/A
- Industry
- BFST Major Banks
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- BFST Finance
- CVAC Health Care
- Exchange
- BFST Nasdaq
- CVAC Nasdaq
- Market Cap
- BFST 838.4M
- CVAC 637.1M
- IPO Year
- BFST 2018
- CVAC 2020
- Fundamental
- Price
- BFST $28.38
- CVAC $2.66
- Analyst Decision
- BFST Buy
- CVAC Hold
- Analyst Count
- BFST 2
- CVAC 3
- Target Price
- BFST $26.00
- CVAC $10.00
- AVG Volume (30 Days)
- BFST 108.9K
- CVAC 576.2K
- Earning Date
- BFST 01-21-2025
- CVAC 11-12-2024
- Dividend Yield
- BFST 1.97%
- CVAC N/A
- EPS Growth
- BFST N/A
- CVAC N/A
- EPS
- BFST 2.32
- CVAC N/A
- Revenue
- BFST $249,883,000.00
- CVAC $70,565,734.00
- Revenue This Year
- BFST N/A
- CVAC $123.97
- Revenue Next Year
- BFST $18.49
- CVAC N/A
- P/E Ratio
- BFST $12.23
- CVAC N/A
- Revenue Growth
- BFST 1.14
- CVAC 75.11
- 52 Week Low
- BFST $18.97
- CVAC $2.22
- 52 Week High
- BFST $30.30
- CVAC $6.30
- Technical
- Relative Strength Index (RSI)
- BFST 57.27
- CVAC 45.65
- Support Level
- BFST $25.13
- CVAC $2.37
- Resistance Level
- BFST $29.27
- CVAC $2.65
- Average True Range (ATR)
- BFST 1.19
- CVAC 0.18
- MACD
- BFST -0.13
- CVAC -0.01
- Stochastic Oscillator
- BFST 62.89
- CVAC 48.33
About BFST Business First Bancshares Inc.
Business First Bancshares Inc is a United States-based bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.